ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals

Status: Enrolling

Conditions: Acute Hepatic Porphyria

Study type: Observational

Funder types: Industry

Identifiers

NCT04883905

ALN-AS1-006

EUPAS43201 (Registry Identifier)

Details and patient eligibility

About

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Enrollment: 150 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of AHP, per physician's determination

Exclusion criteria

• Currently enrolled in a clinical trial for any investigational agent

Trial design

150 participants in 1 patient group

Patients with AHP

Description:

Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.